Tags: Rifaximin View |
Tags: Rifaximin View |
Tags: Rifaximin View |
|||||||||
Tags: Rifaximin View |
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that very little of the drug will pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It is used in the treatment of travelers diarrhea and hepatic encephalopathy, for which it received orphan drug status from the U.S. Food and Drug Administration in 1998.
Iupac Name: (2''S'',16''Z'',18''E'',20''S'',21''S'',22''R'',23''R'',24''R'',25''S'',26''S'',27''S'',28''E'')-,5,6,21,23,25-pentahydroxy-27-methoxy-2,4,11,16,20,22,24,26-,octamethyl-2,7-(epoxypentadeca-1,11,13trienimino)benzofuro,4,5-epyrido1,2-a-benzimida-zole-1,15(2''H'')-dione,25-acetate
Image2: Rifaximin Xifaxan.png
Width2: 139
Number on List: 80621-81-4
Atc Prefix: A07
Atc Suffix: AA11
Atc Supplemental: ATCD06AX11 ATCvetG51AA06 ATCvetJ51XX01
Pubchem: 6436173
Drugbank: APRD01218
C: 43 H = 51 N = 3 O = 11
Molecular Weight: 785.879 g/mol
Bioavailability: < 0.4%
Metabolism: Hepatic (Liver)
Elimination Half-life: 6 hours
Excretion: Fecal (97%)
Pregnancy Us: C
Legal Status: Rx-only
Routes Of Administration: Oral